nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—UGT2B7—Epirubicin—testicular cancer	0.0751	0.0918	CbGbCtD
Ezetimibe—ABCC3—Cisplatin—testicular cancer	0.0689	0.0842	CbGbCtD
Ezetimibe—ABCC3—Etoposide—testicular cancer	0.0677	0.0827	CbGbCtD
Ezetimibe—UGT1A1—Etoposide—testicular cancer	0.0505	0.0618	CbGbCtD
Ezetimibe—ABCG2—Dactinomycin—testicular cancer	0.0493	0.0602	CbGbCtD
Ezetimibe—ABCC3—Doxorubicin—testicular cancer	0.0462	0.0564	CbGbCtD
Ezetimibe—ABCC3—Methotrexate—testicular cancer	0.0447	0.0547	CbGbCtD
Ezetimibe—ABCC2—Carboplatin—testicular cancer	0.0366	0.0448	CbGbCtD
Ezetimibe—ABCC2—Vinblastine—testicular cancer	0.0341	0.0417	CbGbCtD
Ezetimibe—ABCG2—Carboplatin—testicular cancer	0.0331	0.0405	CbGbCtD
Ezetimibe—ABCC2—Cisplatin—testicular cancer	0.0313	0.0383	CbGbCtD
Ezetimibe—ABCC2—Etoposide—testicular cancer	0.0308	0.0376	CbGbCtD
Ezetimibe—ABCG2—Cisplatin—testicular cancer	0.0283	0.0346	CbGbCtD
Ezetimibe—ABCG2—Etoposide—testicular cancer	0.0278	0.034	CbGbCtD
Ezetimibe—SLCO1B1—Methotrexate—testicular cancer	0.0231	0.0283	CbGbCtD
Ezetimibe—ABCC2—Doxorubicin—testicular cancer	0.021	0.0256	CbGbCtD
Ezetimibe—ABCC2—Methotrexate—testicular cancer	0.0203	0.0248	CbGbCtD
Ezetimibe—ABCG2—Doxorubicin—testicular cancer	0.019	0.0232	CbGbCtD
Ezetimibe—ABCG2—Methotrexate—testicular cancer	0.0184	0.0225	CbGbCtD
Ezetimibe—ABCB1—Dactinomycin—testicular cancer	0.0178	0.0217	CbGbCtD
Ezetimibe—CYP3A4—Ifosfamide—testicular cancer	0.0126	0.0154	CbGbCtD
Ezetimibe—ABCB1—Vinblastine—testicular cancer	0.0111	0.0136	CbGbCtD
Ezetimibe—ABCB1—Cisplatin—testicular cancer	0.0102	0.0125	CbGbCtD
Ezetimibe—ABCB1—Etoposide—testicular cancer	0.01	0.0123	CbGbCtD
Ezetimibe—ABCB1—Doxorubicin—testicular cancer	0.00684	0.00836	CbGbCtD
Ezetimibe—CYP3A4—Vinblastine—testicular cancer	0.00667	0.00815	CbGbCtD
Ezetimibe—ABCB1—Methotrexate—testicular cancer	0.00662	0.0081	CbGbCtD
Ezetimibe—CYP3A4—Etoposide—testicular cancer	0.00601	0.00734	CbGbCtD
Ezetimibe—NPC1L1—testis—testicular cancer	0.0051	0.141	CbGeAlD
Ezetimibe—CYP3A4—Doxorubicin—testicular cancer	0.0041	0.00501	CbGbCtD
Ezetimibe—ANPEP—embryo—testicular cancer	0.00342	0.0941	CbGeAlD
Ezetimibe—SOAT1—seminal vesicle—testicular cancer	0.00336	0.0924	CbGeAlD
Ezetimibe—ANPEP—seminal vesicle—testicular cancer	0.00321	0.0884	CbGeAlD
Ezetimibe—SOAT1—gonad—testicular cancer	0.00243	0.0668	CbGeAlD
Ezetimibe—SOAT1—female gonad—testicular cancer	0.00197	0.0543	CbGeAlD
Ezetimibe—ANPEP—female gonad—testicular cancer	0.00189	0.0519	CbGeAlD
Ezetimibe—SOAT1—testis—testicular cancer	0.00175	0.0481	CbGeAlD
Ezetimibe—ANPEP—testis—testicular cancer	0.00167	0.046	CbGeAlD
Ezetimibe—SOAT1—lymph node—testicular cancer	0.00127	0.0349	CbGeAlD
Ezetimibe—UGT2B7—testis—testicular cancer	0.00124	0.0342	CbGeAlD
Ezetimibe—ANPEP—lymph node—testicular cancer	0.00121	0.0334	CbGeAlD
Ezetimibe—ABCC3—female gonad—testicular cancer	0.00094	0.0259	CbGeAlD
Ezetimibe—ABCG2—seminal vesicle—testicular cancer	0.000932	0.0257	CbGeAlD
Ezetimibe—ABCC3—testis—testicular cancer	0.000833	0.0229	CbGeAlD
Ezetimibe—ABCC2—testis—testicular cancer	0.000666	0.0183	CbGeAlD
Ezetimibe—ABCC3—lymph node—testicular cancer	0.000604	0.0166	CbGeAlD
Ezetimibe—ABCG2—female gonad—testicular cancer	0.000548	0.0151	CbGeAlD
Ezetimibe—ABCB1—embryo—testicular cancer	0.000489	0.0135	CbGeAlD
Ezetimibe—ABCG2—testis—testicular cancer	0.000486	0.0134	CbGeAlD
Ezetimibe—ABCC2—lymph node—testicular cancer	0.000483	0.0133	CbGeAlD
Ezetimibe—ABCB1—seminal vesicle—testicular cancer	0.00046	0.0127	CbGeAlD
Ezetimibe—ABCG2—lymph node—testicular cancer	0.000352	0.00969	CbGeAlD
Ezetimibe—ABCB1—gonad—testicular cancer	0.000332	0.00915	CbGeAlD
Ezetimibe—ANPEP—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000308	0.085	CbGpPWpGaD
Ezetimibe—ABCB1—female gonad—testicular cancer	0.00027	0.00743	CbGeAlD
Ezetimibe—ABCB1—testis—testicular cancer	0.000239	0.00659	CbGeAlD
Ezetimibe—Erectile dysfunction—Methotrexate—testicular cancer	0.000217	0.00152	CcSEcCtD
Ezetimibe—Pancreatitis—Epirubicin—testicular cancer	0.000216	0.00152	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Methotrexate—testicular cancer	0.000215	0.00151	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000215	0.0593	CbGpPWpGaD
Ezetimibe—Breast disorder—Doxorubicin—testicular cancer	0.000213	0.0015	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	0.000212	0.00149	CcSEcCtD
Ezetimibe—Decreased appetite—Cisplatin—testicular cancer	0.000212	0.00149	CcSEcCtD
Ezetimibe—Diarrhoea—Dactinomycin—testicular cancer	0.000211	0.00149	CcSEcCtD
Ezetimibe—Nasopharyngitis—Doxorubicin—testicular cancer	0.000211	0.00148	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000211	0.00148	CcSEcCtD
Ezetimibe—Vomiting—Bleomycin—testicular cancer	0.00021	0.00148	CcSEcCtD
Ezetimibe—Infestation NOS—Methotrexate—testicular cancer	0.00021	0.00148	CcSEcCtD
Ezetimibe—Infestation—Methotrexate—testicular cancer	0.00021	0.00148	CcSEcCtD
Ezetimibe—Rash—Bleomycin—testicular cancer	0.000209	0.00147	CcSEcCtD
Ezetimibe—Gastritis—Doxorubicin—testicular cancer	0.000209	0.00147	CcSEcCtD
Ezetimibe—Pain—Cisplatin—testicular cancer	0.000209	0.00147	CcSEcCtD
Ezetimibe—Dermatitis—Bleomycin—testicular cancer	0.000208	0.00147	CcSEcCtD
Ezetimibe—Hypersensitivity—Ifosfamide—testicular cancer	0.000208	0.00147	CcSEcCtD
Ezetimibe—Muscular weakness—Doxorubicin—testicular cancer	0.000208	0.00146	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.000208	0.00146	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000205	0.00144	CcSEcCtD
Ezetimibe—Influenza—Doxorubicin—testicular cancer	0.000204	0.00143	CcSEcCtD
Ezetimibe—Asthenia—Ifosfamide—testicular cancer	0.000203	0.00143	CcSEcCtD
Ezetimibe—Eosinophilia—Doxorubicin—testicular cancer	0.000202	0.00142	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Epirubicin—testicular cancer	0.000201	0.00141	CcSEcCtD
Ezetimibe—Feeling abnormal—Cisplatin—testicular cancer	0.000201	0.00141	CcSEcCtD
Ezetimibe—Paraesthesia—Etoposide—testicular cancer	0.000201	0.00141	CcSEcCtD
Ezetimibe—Pruritus—Ifosfamide—testicular cancer	0.0002	0.00141	CcSEcCtD
Ezetimibe—Pancreatitis—Doxorubicin—testicular cancer	0.0002	0.00141	CcSEcCtD
Ezetimibe—Dyspnoea—Etoposide—testicular cancer	0.000199	0.0014	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Methotrexate—testicular cancer	0.000198	0.0014	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—KITLG—testicular cancer	0.000198	0.0545	CbGpPWpGaD
Ezetimibe—Nausea—Bleomycin—testicular cancer	0.000197	0.00138	CcSEcCtD
Ezetimibe—Infestation—Epirubicin—testicular cancer	0.000196	0.00138	CcSEcCtD
Ezetimibe—Infestation NOS—Epirubicin—testicular cancer	0.000196	0.00138	CcSEcCtD
Ezetimibe—Vomiting—Dactinomycin—testicular cancer	0.000196	0.00138	CcSEcCtD
Ezetimibe—ANPEP—Cardiac Progenitor Differentiation—KIT—testicular cancer	0.000195	0.0538	CbGpPWpGaD
Ezetimibe—Rash—Dactinomycin—testicular cancer	0.000195	0.00137	CcSEcCtD
Ezetimibe—Decreased appetite—Etoposide—testicular cancer	0.000194	0.00137	CcSEcCtD
Ezetimibe—Diarrhoea—Ifosfamide—testicular cancer	0.000194	0.00136	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Etoposide—testicular cancer	0.000193	0.00136	CcSEcCtD
Ezetimibe—Body temperature increased—Cisplatin—testicular cancer	0.000193	0.00136	CcSEcCtD
Ezetimibe—Fatigue—Etoposide—testicular cancer	0.000193	0.00135	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Epirubicin—testicular cancer	0.000192	0.00135	CcSEcCtD
Ezetimibe—Jaundice—Epirubicin—testicular cancer	0.000191	0.00135	CcSEcCtD
Ezetimibe—Constipation—Etoposide—testicular cancer	0.000191	0.00134	CcSEcCtD
Ezetimibe—Pain—Etoposide—testicular cancer	0.000191	0.00134	CcSEcCtD
Ezetimibe—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000189	0.00133	CcSEcCtD
Ezetimibe—Hepatitis—Methotrexate—testicular cancer	0.000188	0.00132	CcSEcCtD
Ezetimibe—Dizziness—Ifosfamide—testicular cancer	0.000187	0.00132	CcSEcCtD
Ezetimibe—Pharyngitis—Methotrexate—testicular cancer	0.000187	0.00132	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000186	0.00131	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Epirubicin—testicular cancer	0.000186	0.00131	CcSEcCtD
Ezetimibe—Sinusitis—Epirubicin—testicular cancer	0.000184	0.0013	CcSEcCtD
Ezetimibe—Feeling abnormal—Etoposide—testicular cancer	0.000184	0.0013	CcSEcCtD
Ezetimibe—Nausea—Dactinomycin—testicular cancer	0.000183	0.00129	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Etoposide—testicular cancer	0.000183	0.00129	CcSEcCtD
Ezetimibe—Infestation—Doxorubicin—testicular cancer	0.000182	0.00128	CcSEcCtD
Ezetimibe—Infestation NOS—Doxorubicin—testicular cancer	0.000182	0.00128	CcSEcCtD
Ezetimibe—Vomiting—Ifosfamide—testicular cancer	0.00018	0.00127	CcSEcCtD
Ezetimibe—Hypersensitivity—Cisplatin—testicular cancer	0.00018	0.00126	CcSEcCtD
Ezetimibe—ABCG8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000179	0.0495	CbGpPWpGaD
Ezetimibe—Rash—Ifosfamide—testicular cancer	0.000178	0.00125	CcSEcCtD
Ezetimibe—Dermatitis—Ifosfamide—testicular cancer	0.000178	0.00125	CcSEcCtD
Ezetimibe—Erythema multiforme—Methotrexate—testicular cancer	0.000178	0.00125	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000178	0.00125	CcSEcCtD
Ezetimibe—Urticaria—Etoposide—testicular cancer	0.000177	0.00125	CcSEcCtD
Ezetimibe—Jaundice—Doxorubicin—testicular cancer	0.000177	0.00125	CcSEcCtD
Ezetimibe—Abdominal pain—Etoposide—testicular cancer	0.000177	0.00124	CcSEcCtD
Ezetimibe—Body temperature increased—Etoposide—testicular cancer	0.000177	0.00124	CcSEcCtD
Ezetimibe—Hepatitis—Epirubicin—testicular cancer	0.000176	0.00124	CcSEcCtD
Ezetimibe—Asthenia—Cisplatin—testicular cancer	0.000175	0.00123	CcSEcCtD
Ezetimibe—Pharyngitis—Epirubicin—testicular cancer	0.000175	0.00123	CcSEcCtD
Ezetimibe—Oedema peripheral—Epirubicin—testicular cancer	0.000174	0.00122	CcSEcCtD
Ezetimibe—ABCB1—lymph node—testicular cancer	0.000174	0.00478	CbGeAlD
Ezetimibe—Connective tissue disorder—Epirubicin—testicular cancer	0.000173	0.00122	CcSEcCtD
Ezetimibe—ABCG5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000172	0.0476	CbGpPWpGaD
Ezetimibe—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000172	0.00121	CcSEcCtD
Ezetimibe—UGT2B15—Phase II conjugation—HPGDS—testicular cancer	0.000171	0.0474	CbGpPWpGaD
Ezetimibe—Angiopathy—Methotrexate—testicular cancer	0.000171	0.0012	CcSEcCtD
Ezetimibe—Sinusitis—Doxorubicin—testicular cancer	0.00017	0.0012	CcSEcCtD
Ezetimibe—Immune system disorder—Methotrexate—testicular cancer	0.00017	0.0012	CcSEcCtD
Ezetimibe—Mediastinal disorder—Methotrexate—testicular cancer	0.00017	0.00119	CcSEcCtD
Ezetimibe—UGT1A3—NRF2 pathway—SLC2A6—testicular cancer	0.000169	0.0466	CbGpPWpGaD
Ezetimibe—Nausea—Ifosfamide—testicular cancer	0.000168	0.00118	CcSEcCtD
Ezetimibe—Diarrhoea—Cisplatin—testicular cancer	0.000167	0.00117	CcSEcCtD
Ezetimibe—Erythema multiforme—Epirubicin—testicular cancer	0.000167	0.00117	CcSEcCtD
Ezetimibe—Alopecia—Methotrexate—testicular cancer	0.000166	0.00117	CcSEcCtD
Ezetimibe—Mental disorder—Methotrexate—testicular cancer	0.000165	0.00116	CcSEcCtD
Ezetimibe—Hypersensitivity—Etoposide—testicular cancer	0.000165	0.00116	CcSEcCtD
Ezetimibe—Erythema—Methotrexate—testicular cancer	0.000164	0.00115	CcSEcCtD
Ezetimibe—Malnutrition—Methotrexate—testicular cancer	0.000164	0.00115	CcSEcCtD
Ezetimibe—Flushing—Epirubicin—testicular cancer	0.000164	0.00115	CcSEcCtD
Ezetimibe—Hepatitis—Doxorubicin—testicular cancer	0.000163	0.00115	CcSEcCtD
Ezetimibe—Pharyngitis—Doxorubicin—testicular cancer	0.000162	0.00114	CcSEcCtD
Ezetimibe—Oedema peripheral—Doxorubicin—testicular cancer	0.000161	0.00113	CcSEcCtD
Ezetimibe—Asthenia—Etoposide—testicular cancer	0.00016	0.00113	CcSEcCtD
Ezetimibe—Connective tissue disorder—Doxorubicin—testicular cancer	0.00016	0.00113	CcSEcCtD
Ezetimibe—Angiopathy—Epirubicin—testicular cancer	0.00016	0.00112	CcSEcCtD
Ezetimibe—Immune system disorder—Epirubicin—testicular cancer	0.000159	0.00112	CcSEcCtD
Ezetimibe—Mediastinal disorder—Epirubicin—testicular cancer	0.000159	0.00112	CcSEcCtD
Ezetimibe—Back pain—Methotrexate—testicular cancer	0.000159	0.00112	CcSEcCtD
Ezetimibe—Pruritus—Etoposide—testicular cancer	0.000158	0.00111	CcSEcCtD
Ezetimibe—Alopecia—Epirubicin—testicular cancer	0.000156	0.0011	CcSEcCtD
Ezetimibe—Vomiting—Cisplatin—testicular cancer	0.000155	0.00109	CcSEcCtD
Ezetimibe—Mental disorder—Epirubicin—testicular cancer	0.000154	0.00109	CcSEcCtD
Ezetimibe—Erythema multiforme—Doxorubicin—testicular cancer	0.000154	0.00108	CcSEcCtD
Ezetimibe—Rash—Cisplatin—testicular cancer	0.000154	0.00108	CcSEcCtD
Ezetimibe—Dermatitis—Cisplatin—testicular cancer	0.000154	0.00108	CcSEcCtD
Ezetimibe—Erythema—Epirubicin—testicular cancer	0.000153	0.00108	CcSEcCtD
Ezetimibe—Malnutrition—Epirubicin—testicular cancer	0.000153	0.00108	CcSEcCtD
Ezetimibe—Diarrhoea—Etoposide—testicular cancer	0.000153	0.00108	CcSEcCtD
Ezetimibe—Ill-defined disorder—Methotrexate—testicular cancer	0.000152	0.00107	CcSEcCtD
Ezetimibe—Anaemia—Methotrexate—testicular cancer	0.000152	0.00107	CcSEcCtD
Ezetimibe—Flushing—Doxorubicin—testicular cancer	0.000151	0.00106	CcSEcCtD
Ezetimibe—Flatulence—Epirubicin—testicular cancer	0.000151	0.00106	CcSEcCtD
Ezetimibe—Back pain—Epirubicin—testicular cancer	0.000148	0.00104	CcSEcCtD
Ezetimibe—Angiopathy—Doxorubicin—testicular cancer	0.000148	0.00104	CcSEcCtD
Ezetimibe—Malaise—Methotrexate—testicular cancer	0.000148	0.00104	CcSEcCtD
Ezetimibe—Dizziness—Etoposide—testicular cancer	0.000148	0.00104	CcSEcCtD
Ezetimibe—Muscle spasms—Epirubicin—testicular cancer	0.000148	0.00104	CcSEcCtD
Ezetimibe—Immune system disorder—Doxorubicin—testicular cancer	0.000147	0.00104	CcSEcCtD
Ezetimibe—Mediastinal disorder—Doxorubicin—testicular cancer	0.000147	0.00103	CcSEcCtD
Ezetimibe—Nausea—Cisplatin—testicular cancer	0.000145	0.00102	CcSEcCtD
Ezetimibe—Alopecia—Doxorubicin—testicular cancer	0.000144	0.00101	CcSEcCtD
Ezetimibe—ABCC3—NRF2 pathway—SLC2A6—testicular cancer	0.000144	0.0396	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—SLC2A6—testicular cancer	0.000144	0.0396	CbGpPWpGaD
Ezetimibe—Cough—Methotrexate—testicular cancer	0.000143	0.00101	CcSEcCtD
Ezetimibe—Mental disorder—Doxorubicin—testicular cancer	0.000143	0.00101	CcSEcCtD
Ezetimibe—Ill-defined disorder—Epirubicin—testicular cancer	0.000142	0.001	CcSEcCtD
Ezetimibe—Vomiting—Etoposide—testicular cancer	0.000142	0.000999	CcSEcCtD
Ezetimibe—Malnutrition—Doxorubicin—testicular cancer	0.000142	0.000999	CcSEcCtD
Ezetimibe—Erythema—Doxorubicin—testicular cancer	0.000142	0.000999	CcSEcCtD
Ezetimibe—Anaemia—Epirubicin—testicular cancer	0.000142	0.000998	CcSEcCtD
Ezetimibe—Rash—Etoposide—testicular cancer	0.000141	0.000991	CcSEcCtD
Ezetimibe—Dermatitis—Etoposide—testicular cancer	0.000141	0.00099	CcSEcCtD
Ezetimibe—Headache—Etoposide—testicular cancer	0.00014	0.000985	CcSEcCtD
Ezetimibe—Flatulence—Doxorubicin—testicular cancer	0.00014	0.000984	CcSEcCtD
Ezetimibe—Arthralgia—Methotrexate—testicular cancer	0.00014	0.000982	CcSEcCtD
Ezetimibe—Myalgia—Methotrexate—testicular cancer	0.00014	0.000982	CcSEcCtD
Ezetimibe—Chest pain—Methotrexate—testicular cancer	0.00014	0.000982	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000139	0.000975	CcSEcCtD
Ezetimibe—Malaise—Epirubicin—testicular cancer	0.000138	0.000973	CcSEcCtD
Ezetimibe—Discomfort—Methotrexate—testicular cancer	0.000138	0.00097	CcSEcCtD
Ezetimibe—Back pain—Doxorubicin—testicular cancer	0.000137	0.000966	CcSEcCtD
Ezetimibe—Muscle spasms—Doxorubicin—testicular cancer	0.000136	0.00096	CcSEcCtD
Ezetimibe—Palpitations—Epirubicin—testicular cancer	0.000136	0.000954	CcSEcCtD
Ezetimibe—Confusional state—Methotrexate—testicular cancer	0.000135	0.000949	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—KIT—testicular cancer	0.000135	0.0372	CbGpPWpGaD
Ezetimibe—Cough—Epirubicin—testicular cancer	0.000134	0.000942	CcSEcCtD
Ezetimibe—Anaphylactic shock—Methotrexate—testicular cancer	0.000134	0.000941	CcSEcCtD
Ezetimibe—Infection—Methotrexate—testicular cancer	0.000133	0.000935	CcSEcCtD
Ezetimibe—Nausea—Etoposide—testicular cancer	0.000133	0.000933	CcSEcCtD
Ezetimibe—Hypertension—Epirubicin—testicular cancer	0.000132	0.000932	CcSEcCtD
Ezetimibe—Ill-defined disorder—Doxorubicin—testicular cancer	0.000132	0.000927	CcSEcCtD
Ezetimibe—Nervous system disorder—Methotrexate—testicular cancer	0.000131	0.000923	CcSEcCtD
Ezetimibe—Anaemia—Doxorubicin—testicular cancer	0.000131	0.000923	CcSEcCtD
Ezetimibe—Thrombocytopenia—Methotrexate—testicular cancer	0.000131	0.000922	CcSEcCtD
Ezetimibe—Arthralgia—Epirubicin—testicular cancer	0.000131	0.000919	CcSEcCtD
Ezetimibe—Chest pain—Epirubicin—testicular cancer	0.000131	0.000919	CcSEcCtD
Ezetimibe—Myalgia—Epirubicin—testicular cancer	0.000131	0.000919	CcSEcCtD
Ezetimibe—Skin disorder—Methotrexate—testicular cancer	0.00013	0.000914	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00013	0.000913	CcSEcCtD
Ezetimibe—Discomfort—Epirubicin—testicular cancer	0.000129	0.000908	CcSEcCtD
Ezetimibe—Malaise—Doxorubicin—testicular cancer	0.000128	0.000901	CcSEcCtD
Ezetimibe—Dry mouth—Epirubicin—testicular cancer	0.000128	0.000899	CcSEcCtD
Ezetimibe—Confusional state—Epirubicin—testicular cancer	0.000126	0.000888	CcSEcCtD
Ezetimibe—Palpitations—Doxorubicin—testicular cancer	0.000125	0.000883	CcSEcCtD
Ezetimibe—Anaphylactic shock—Epirubicin—testicular cancer	0.000125	0.000881	CcSEcCtD
Ezetimibe—Infection—Epirubicin—testicular cancer	0.000124	0.000875	CcSEcCtD
Ezetimibe—Cough—Doxorubicin—testicular cancer	0.000124	0.000872	CcSEcCtD
Ezetimibe—Nervous system disorder—Epirubicin—testicular cancer	0.000123	0.000864	CcSEcCtD
Ezetimibe—Thrombocytopenia—Epirubicin—testicular cancer	0.000123	0.000863	CcSEcCtD
Ezetimibe—Hypertension—Doxorubicin—testicular cancer	0.000123	0.000862	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000122	0.000858	CcSEcCtD
Ezetimibe—Skin disorder—Epirubicin—testicular cancer	0.000122	0.000856	CcSEcCtD
Ezetimibe—Insomnia—Methotrexate—testicular cancer	0.000121	0.000851	CcSEcCtD
Ezetimibe—Myalgia—Doxorubicin—testicular cancer	0.000121	0.00085	CcSEcCtD
Ezetimibe—Chest pain—Doxorubicin—testicular cancer	0.000121	0.00085	CcSEcCtD
Ezetimibe—Arthralgia—Doxorubicin—testicular cancer	0.000121	0.00085	CcSEcCtD
Ezetimibe—Paraesthesia—Methotrexate—testicular cancer	0.00012	0.000845	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00012	0.000844	CcSEcCtD
Ezetimibe—Discomfort—Doxorubicin—testicular cancer	0.000119	0.00084	CcSEcCtD
Ezetimibe—Dyspnoea—Methotrexate—testicular cancer	0.000119	0.000839	CcSEcCtD
Ezetimibe—Dry mouth—Doxorubicin—testicular cancer	0.000118	0.000832	CcSEcCtD
Ezetimibe—Dyspepsia—Methotrexate—testicular cancer	0.000118	0.000829	CcSEcCtD
Ezetimibe—Confusional state—Doxorubicin—testicular cancer	0.000117	0.000822	CcSEcCtD
Ezetimibe—UGT1A1—NRF2 pathway—SLC2A6—testicular cancer	0.000117	0.0322	CbGpPWpGaD
Ezetimibe—Decreased appetite—Methotrexate—testicular cancer	0.000116	0.000818	CcSEcCtD
Ezetimibe—Anaphylactic shock—Doxorubicin—testicular cancer	0.000116	0.000815	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000116	0.000813	CcSEcCtD
Ezetimibe—Fatigue—Methotrexate—testicular cancer	0.000115	0.000812	CcSEcCtD
Ezetimibe—Infection—Doxorubicin—testicular cancer	0.000115	0.00081	CcSEcCtD
Ezetimibe—Pain—Methotrexate—testicular cancer	0.000114	0.000805	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000114	0.000803	CcSEcCtD
Ezetimibe—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.000114	0.0314	CbGpPWpGaD
Ezetimibe—Nervous system disorder—Doxorubicin—testicular cancer	0.000114	0.000799	CcSEcCtD
Ezetimibe—Thrombocytopenia—Doxorubicin—testicular cancer	0.000113	0.000798	CcSEcCtD
Ezetimibe—Insomnia—Epirubicin—testicular cancer	0.000113	0.000797	CcSEcCtD
Ezetimibe—Skin disorder—Doxorubicin—testicular cancer	0.000113	0.000792	CcSEcCtD
Ezetimibe—Paraesthesia—Epirubicin—testicular cancer	0.000112	0.000791	CcSEcCtD
Ezetimibe—Dyspnoea—Epirubicin—testicular cancer	0.000112	0.000785	CcSEcCtD
Ezetimibe—Feeling abnormal—Methotrexate—testicular cancer	0.00011	0.000776	CcSEcCtD
Ezetimibe—Dyspepsia—Epirubicin—testicular cancer	0.00011	0.000775	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Methotrexate—testicular cancer	0.000109	0.00077	CcSEcCtD
Ezetimibe—Decreased appetite—Epirubicin—testicular cancer	0.000109	0.000766	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000108	0.000761	CcSEcCtD
Ezetimibe—Fatigue—Epirubicin—testicular cancer	0.000108	0.000759	CcSEcCtD
Ezetimibe—Constipation—Epirubicin—testicular cancer	0.000107	0.000753	CcSEcCtD
Ezetimibe—Pain—Epirubicin—testicular cancer	0.000107	0.000753	CcSEcCtD
Ezetimibe—Urticaria—Methotrexate—testicular cancer	0.000106	0.000748	CcSEcCtD
Ezetimibe—Body temperature increased—Methotrexate—testicular cancer	0.000106	0.000744	CcSEcCtD
Ezetimibe—Abdominal pain—Methotrexate—testicular cancer	0.000106	0.000744	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000106	0.000743	CcSEcCtD
Ezetimibe—Insomnia—Doxorubicin—testicular cancer	0.000105	0.000737	CcSEcCtD
Ezetimibe—Paraesthesia—Doxorubicin—testicular cancer	0.000104	0.000732	CcSEcCtD
Ezetimibe—Dyspnoea—Doxorubicin—testicular cancer	0.000103	0.000727	CcSEcCtD
Ezetimibe—Feeling abnormal—Epirubicin—testicular cancer	0.000103	0.000726	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Epirubicin—testicular cancer	0.000102	0.00072	CcSEcCtD
Ezetimibe—Dyspepsia—Doxorubicin—testicular cancer	0.000102	0.000718	CcSEcCtD
Ezetimibe—Decreased appetite—Doxorubicin—testicular cancer	0.000101	0.000709	CcSEcCtD
Ezetimibe—UGT2B15—Biological oxidations—HPGDS—testicular cancer	0.0001	0.0277	CbGpPWpGaD
Ezetimibe—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.0001	0.000704	CcSEcCtD
Ezetimibe—Fatigue—Doxorubicin—testicular cancer	9.99e-05	0.000703	CcSEcCtD
Ezetimibe—Urticaria—Epirubicin—testicular cancer	9.95e-05	0.0007	CcSEcCtD
Ezetimibe—Constipation—Doxorubicin—testicular cancer	9.91e-05	0.000697	CcSEcCtD
Ezetimibe—Pain—Doxorubicin—testicular cancer	9.91e-05	0.000697	CcSEcCtD
Ezetimibe—Body temperature increased—Epirubicin—testicular cancer	9.9e-05	0.000696	CcSEcCtD
Ezetimibe—Abdominal pain—Epirubicin—testicular cancer	9.9e-05	0.000696	CcSEcCtD
Ezetimibe—Hypersensitivity—Methotrexate—testicular cancer	9.86e-05	0.000694	CcSEcCtD
Ezetimibe—Asthenia—Methotrexate—testicular cancer	9.6e-05	0.000675	CcSEcCtD
Ezetimibe—Feeling abnormal—Doxorubicin—testicular cancer	9.55e-05	0.000672	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Doxorubicin—testicular cancer	9.47e-05	0.000667	CcSEcCtD
Ezetimibe—Pruritus—Methotrexate—testicular cancer	9.47e-05	0.000666	CcSEcCtD
Ezetimibe—Hypersensitivity—Epirubicin—testicular cancer	9.23e-05	0.000649	CcSEcCtD
Ezetimibe—Urticaria—Doxorubicin—testicular cancer	9.2e-05	0.000648	CcSEcCtD
Ezetimibe—UGT1A3—Phase II conjugation—HPGDS—testicular cancer	9.19e-05	0.0254	CbGpPWpGaD
Ezetimibe—Body temperature increased—Doxorubicin—testicular cancer	9.16e-05	0.000644	CcSEcCtD
Ezetimibe—Abdominal pain—Doxorubicin—testicular cancer	9.16e-05	0.000644	CcSEcCtD
Ezetimibe—Diarrhoea—Methotrexate—testicular cancer	9.15e-05	0.000644	CcSEcCtD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.02e-05	0.0249	CbGpPWpGaD
Ezetimibe—Asthenia—Epirubicin—testicular cancer	8.98e-05	0.000632	CcSEcCtD
Ezetimibe—Pruritus—Epirubicin—testicular cancer	8.86e-05	0.000623	CcSEcCtD
Ezetimibe—Dizziness—Methotrexate—testicular cancer	8.85e-05	0.000622	CcSEcCtD
Ezetimibe—Diarrhoea—Epirubicin—testicular cancer	8.57e-05	0.000603	CcSEcCtD
Ezetimibe—Hypersensitivity—Doxorubicin—testicular cancer	8.54e-05	0.000601	CcSEcCtD
Ezetimibe—Vomiting—Methotrexate—testicular cancer	8.51e-05	0.000599	CcSEcCtD
Ezetimibe—Rash—Methotrexate—testicular cancer	8.44e-05	0.000594	CcSEcCtD
Ezetimibe—Dermatitis—Methotrexate—testicular cancer	8.43e-05	0.000593	CcSEcCtD
Ezetimibe—Headache—Methotrexate—testicular cancer	8.38e-05	0.00059	CcSEcCtD
Ezetimibe—Asthenia—Doxorubicin—testicular cancer	8.31e-05	0.000585	CcSEcCtD
Ezetimibe—Dizziness—Epirubicin—testicular cancer	8.28e-05	0.000583	CcSEcCtD
Ezetimibe—Pruritus—Doxorubicin—testicular cancer	8.2e-05	0.000577	CcSEcCtD
Ezetimibe—Vomiting—Epirubicin—testicular cancer	7.96e-05	0.00056	CcSEcCtD
Ezetimibe—Nausea—Methotrexate—testicular cancer	7.95e-05	0.000559	CcSEcCtD
Ezetimibe—Diarrhoea—Doxorubicin—testicular cancer	7.93e-05	0.000558	CcSEcCtD
Ezetimibe—Rash—Epirubicin—testicular cancer	7.89e-05	0.000555	CcSEcCtD
Ezetimibe—Dermatitis—Epirubicin—testicular cancer	7.89e-05	0.000555	CcSEcCtD
Ezetimibe—Headache—Epirubicin—testicular cancer	7.84e-05	0.000552	CcSEcCtD
Ezetimibe—UGT2B7—Phase II conjugation—HPGDS—testicular cancer	7.81e-05	0.0216	CbGpPWpGaD
Ezetimibe—Dizziness—Doxorubicin—testicular cancer	7.66e-05	0.000539	CcSEcCtD
Ezetimibe—Nausea—Epirubicin—testicular cancer	7.44e-05	0.000523	CcSEcCtD
Ezetimibe—Vomiting—Doxorubicin—testicular cancer	7.37e-05	0.000518	CcSEcCtD
Ezetimibe—Rash—Doxorubicin—testicular cancer	7.31e-05	0.000514	CcSEcCtD
Ezetimibe—Dermatitis—Doxorubicin—testicular cancer	7.3e-05	0.000513	CcSEcCtD
Ezetimibe—Headache—Doxorubicin—testicular cancer	7.26e-05	0.000511	CcSEcCtD
Ezetimibe—Nausea—Doxorubicin—testicular cancer	6.88e-05	0.000484	CcSEcCtD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.84e-05	0.0189	CbGpPWpGaD
Ezetimibe—SLCO1B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	6.74e-05	0.0186	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.58e-05	0.0182	CbGpPWpGaD
Ezetimibe—UGT1A1—Phase II conjugation—HPGDS—testicular cancer	6.35e-05	0.0175	CbGpPWpGaD
Ezetimibe—UGT1A3—Biological oxidations—HPGDS—testicular cancer	5.37e-05	0.0148	CbGpPWpGaD
Ezetimibe—ABCC3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.6e-05	0.0127	CbGpPWpGaD
Ezetimibe—UGT2B7—Biological oxidations—HPGDS—testicular cancer	4.57e-05	0.0126	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—HPGDS—testicular cancer	4.02e-05	0.0111	CbGpPWpGaD
Ezetimibe—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.95e-05	0.0109	CbGpPWpGaD
Ezetimibe—UGT1A1—Biological oxidations—HPGDS—testicular cancer	3.71e-05	0.0103	CbGpPWpGaD
Ezetimibe—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.64e-05	0.0101	CbGpPWpGaD
Ezetimibe—SLCO1B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.42e-05	0.00945	CbGpPWpGaD
Ezetimibe—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.17e-05	0.00875	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—HPGDS—testicular cancer	3.05e-05	0.00841	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—HPGDS—testicular cancer	2.93e-05	0.0081	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—STK11—testicular cancer	2.92e-05	0.00806	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—MMP2—testicular cancer	2.23e-05	0.00617	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—STK11—testicular cancer	2.21e-05	0.00611	CbGpPWpGaD
Ezetimibe—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	2.13e-05	0.00589	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—STK11—testicular cancer	2.13e-05	0.00588	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.75e-05	0.00485	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—HPGDS—testicular cancer	1.72e-05	0.00474	CbGpPWpGaD
Ezetimibe—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.71e-05	0.00473	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.57e-05	0.00433	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.31e-05	0.00361	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—STK11—testicular cancer	1.25e-05	0.00344	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.14e-05	0.00314	CbGpPWpGaD
Ezetimibe—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.05e-05	0.0029	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—HPGDS—testicular cancer	9.19e-06	0.00254	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—HPGDS—testicular cancer	7.81e-06	0.00216	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—HPGDS—testicular cancer	7.81e-06	0.00216	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—STK11—testicular cancer	6.68e-06	0.00184	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—HPGDS—testicular cancer	6.35e-06	0.00175	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—HPGDS—testicular cancer	5.82e-06	0.00161	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—STK11—testicular cancer	5.68e-06	0.00157	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—STK11—testicular cancer	5.68e-06	0.00157	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—HPGDS—testicular cancer	5.39e-06	0.00149	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—STK11—testicular cancer	4.61e-06	0.00127	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—STK11—testicular cancer	4.23e-06	0.00117	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—STK11—testicular cancer	3.91e-06	0.00108	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—HPGDS—testicular cancer	2.91e-06	0.000804	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—STK11—testicular cancer	2.12e-06	0.000584	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—HPGDS—testicular cancer	1.79e-06	0.000496	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—STK11—testicular cancer	1.3e-06	0.00036	CbGpPWpGaD
